N/A N=3,345 Modified Instrumentation for Surgery to Correct Trichiasis
Trachoma
Primary: Number of Eyelids With Presence of Recurrent Trichiasis — 948; 1062; 721; 612 eyelids
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=4,914 Maximizing Trichiasis Surgery Success
Trichiasis · Surgery
Primary: Number of Eyes With Presence of Post-Operative Trichiasis Within 12 Months — 347; 504; 298 eyes — p=0.039
N/A N=27,473 Identification of TT Cases by Community Treatment Assistants: An Assessment
Trichiasis
Primary: TT Cases Screened Positive by CTA's and Confirmed by Graders — 9; 50 Participants
N/A N=700 Repeat Surgery for Patients With Post-operative Trachomatous Trichiasis Trial
Trichiasis · Surgery
Primary: Number of Eyelids With Post-operative Trichiasis Within 12 Months — 94; 120 Eyelids — p=0.07
Phase 4 N=1,452 Study of Azithromycin to Prevent Recurrent Trichiasis Following Surgery in Ethiopia
Trichiasis
Primary: Recurrent Trichiasis in Tetracycline and Azithromycin Groups — 45; 62 Participants — p=.047
Phase 4 N=128 Partnership for Rapid Elimination of Trachoma
Trachoma
Primary: Community Prevalence of Trachoma and Ocular C. Trachomatis (CT) Infection at Baseline — 30.7; 30.3; 31.1; 30.5 community
Phase 3 N=2,410 FLuorometholone as Adjunctive MEdical Therapy for TT Surgery (FLAME) Trial
Trachomatous Trichiasis (TT) · Eye Diseases · Eyelid Diseases
Primary: Incidence of Postoperative TT by One Year, as Determined by Trained Study Team Members — 218; 213; 32; 36 Study eyes — p=0.97
N/A N=212 Tube Versus Trabeculectomy (TVT) Study
Glaucoma
Primary: Change in Intraocular Pressure — 12.6; 14.4 mm Hg
Phase 1 N=17 Demodex Blepharitis Treatment Study
Chronic Blepharitis
Primary: Change in the Number of Demodex Mites — -3; -0.4 Mites
Phase 4 N=1,347 Impact of Two Alternative Dosing Strategies for Trachoma Control in Niger
Trachoma · Chlamydia Trachomatis
Primary: Infection With Chlamydia Trachomatis Diagnosed by Use of NAATs [Nucleic Acid Amplification Test] — 57; 42; 5; 3 Participants
N/A N=52 A Surveillance and Azithromycin Treatment for Newcomers and Travelers Evaluation: The ASANTE Trial
Trachoma
Primary: The Proportion of Communities With C. Trachomatis Infection Prevalence of 1% or Below — 7; 4 community — p=>0.05
Phase 1 N=19 CLN-0045: Safety, and Efficacy of OTX-TIC in Participants With Open Angle Glaucoma or Ocular Hypertension
Ocular Hypertension · Open Angle Glaucoma
Primary: Ocular Treatment Emergent Adverse Events — 9; 7; 9; 1 Number of Treatment-Emergent Events
Phase 4 N=242 Primary Tube Versus Trabeculectomy Study
Glaucoma
Primary: Number of Participants With Surgical Failure — 31; 23; 18; 9 Participants
Phase 3 N=53 Evaluation of the Tympanostomy Tube Delivery System
Otitis Media With Effusion · Acute Otitis Media
Primary: Safety of Tympanostomy Tube (TT) Delivery System — 0.0 percentage of ears
Phase 3 N=421 Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis
Blepharitis
Primary: Proportion of Participants Cured Based on a Collarette Score at Day 43. — 0.439; 0.072 Proportion cured
N/A N=25 Singapore Tympanostomy Tube Delivery System Study
Otitis Media
Primary: Percentage of Ears Treated Successfully With the TTDS in the Absence of Acute Intraprocedural Adverse Events. — 94.6 percentage of ears
Phase 3 N=565 Phase 3 Study Evaluating Safety and Efficacy of OTX-TP in Subjects With OAG or OHT
Open Angle Glaucoma · Ocular Hypertension
Primary: Mean IOP — 21; 22.9; 20.2; 21.9 mmHg
N/A N=21 Evaluate the Safety and Effectiveness of The Tixel Fractional System in the Treatment of Meibomian Gland Disfunction
Dry Eye Syndromes · Dry Eye · Meibomian Gland Dysfunction
Primary: Score and Change From Baseline in Tear Break Up Times (TBUT), as Assessed by a Masked Rater — 4.0; 1.9; 3.4; 4.7 seconds
N/A N=42 The Effect of Oral Azithromycin in the Treatment of Chlamydial Conjunctivitis
Chlamydial Conjunctivitis
Primary: Total Number of Participants With Negative Chlamydia Direct Fluorescent Antibody (DFA) Test Results After Oral Azithromycin Treatments — 27 participants
N/A N=150 Chalazion Conservative Treatment Trial
Chalazion Unspecified Eye, Unspecified Eyelid · Chalazion Left Eye, Unspecified Eyelid · Chalazion Right Eye, Unspecified Eyelid
Primary: Number of Participants With Complete Resolution — 13; 12; 11 participants
Phase 4 N=3,931 Azithromycin Reduction to Reach Elimination of Trachoma
Trachoma
Primary: Ocular Chlamydia Measured in a Population-based Sample of 0-9 Year-old Children — 0; 0 Participants
Phase 4 N=62 A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease
Thyroid Eye Disease · Chronic (Inactive) Thyroid Eye Disease
Primary: Change From Baseline in Proptosis of Study Eye at Week 24 — -2.41; -0.92 Millimieter (mm) — p=0.0004
N/A N=16 Clinical Study of the Tympanostomy Tube Delivery System
Otitis Media With Effusion
Primary: Device Success — 21 devices
Phase 2 N=16 A Study to Evaluate TRS01 Eye Drops in Participants With Active Non-infectious Anterior Uveitis
Non-infectious Anterior Uveitis
Primary: Assessment of Both Systemic and Ocular Adverse Events — 2; 5 Participants
Phase 2 N=37 A Study of TRS01 in Participants With Post-surgical Ocular Inflammation
Post Surgical Ocular Inflammation
Primary: Assessment of Both Systemic and Ocular Adverse Events — 0; 3; 0; 0 Number of TEAE
N/A N=98 TRILUMINATE Study With Abbott Transcatheter Clip Repair System in Patients With Moderate or Greater TR
Tricuspid Valve Insufficiency
Primary: Number of Participants With Echocardiographic Tricuspid Regurgitation Reduction at Least 1 Grade — 71 Participants
Phase 3 N=412 Trial to Evaluate the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis
Blepharitis
Primary: The Proportion of Participants Cured Based on Their Collarette Score of 0 for the Upper Eyelid. — 0.547; 0.122 Proportion cured
Phase 3 N=705 Phase III Clinical Trial of TRAVATAN Z in Ocular Surface Health
Open-angle Glaucoma · Ocular Hypertension
Primary: Mean Change at Day 90 From Baseline (Day 0) in Ocular Surface Disease Index (OSDI) Score — -9.1; -10.2 Units on a scale
Phase 4 N=30 Travoprost 0.004% Versus Pilocarpine 1% in Patients With Chronic Angle Closure Glaucoma (CACG)
Angle-closure Glaucoma
Primary: Mean Intraocular Pressure (IOP) — 15.77; 18.35 millimeters mercury (mm Hg)
Phase 3 N=152 Efficacy and Safety Assessment of T4020 Versus Vehicule in Patients With Chronic Neurotrophic Keratitis or Corneal Ulcer
Keratitis · Corneal Ulcer
Primary: Number of Participants With a Reduction in Neurotrophic the Keratitis/Ulcer Area on Day28 — 37; 44 Participants